The revenue miss is lumpy partner math: last year's quarter carried a $50 million Sanofi milestone, this one only a $10 million Gilead option payment. What matters more is the $287.7 million cash pile against a $146 million market cap, funding operations through 2028 and into ADC readouts for MGC028 and MGC026 in 2027.
Latest Activity
MGNX Coverage
Barclays Picks 2 Winners and 2 Losers After Earnings
Barclays recently issued a few calls across multiple industries picking a couple winners and a couple losers.